We are pleased to announce that our first LEAP Paper has been published.
In our studies, ligand-based exosome affinity purification (LEAP) technology has proven to be an efficient, robust, scalable, low-cost, and highly reproducible EV purification platform technology.
The patented technology is suited to the manufacture of naive EV and engineered EV products. When compared with other models, LEAP offers a combination of advantages and the supporting data provided points to a proprietary answer to the downstream processing bottleneck.
Access the paper on BioProcess International here.